Better Health for All

Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Its entire business is devoted to health improvement, with lead product candidate atacicept showing statistically significant reductions in urine protein creatinine ratio (UPCR), galactose-deficient IgA1 (Gd-IgA1), and hematuria, with stable estimated glomerular filtration rate (eGFR) in a Phase 2b clinical trial for IgA nephropathy (IgAN).

The safety profile of atacicept in this trial was comparable to placebo. The company is also developing MAU868 for reactivated BK virus (BKV) infections. As a development-stage company, it reported net losses of $33.7 million for the three months ended June 30, 2024, and $62.1 million for the six months ended June 30, 2024, and has no current revenue from harmful products. Research and development expenses were $29.3 million for the three months ended June 30, 2024, and $52.5 million for the six months ended June 30, 2024. The company is subject to environmental, health, and safety laws and regulations concerning hazardous materials and wastes, and is required to comply with GCP requirements for clinical trials. It is also subject to stringent data privacy and security laws and acknowledges that its business may be adversely affected by geopolitical and macroeconomic developments.

Fair Money & Economic Opportunity

Vera Therapeutics, Inc. is a biotechnology company focused on developing treatments for immunological diseases.

It does not operate as a financial institution, nor does it offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its core business model. The company's financial activities, such as its corporate credit facility with Oxford Finance LLC, pertain to its own corporate financing and not to consumer financial services.

Fair Pay & Worker Respect

Vera Therapeutics offers medical, dental, and vision insurance to all employees, including named executive officers, on the same basis.

The company also pays the premiums for medical, disability, and accidental death and dismemberment insurance for all employees. Additionally, the company maintains a 401(k) plan, making matching or discretionary contributions up to $3,000 per employee per year, with total matching contributions of $142,000 in 2023 and $95,000 in 2022. The company has a Code of Business Conduct and Ethics applicable to all employees, officers, and directors, and its Compensation Committee reviews employee diversity and inclusion initiatives and human capital management policies.

Honest & Fair Business

Vera Therapeutics, Inc. has a 'Policy on Misconduct Reporting, Investigation and Non-Retaliation,' which includes a compliance hotline (833-831-0544) and an online reporting portal.

Employees are required to sign an annual acknowledgment of the Code of Business Conduct and Ethics, and periodic training sessions are held. However, the effectiveness of the program, such as uptake rates or resolution times, is not publicly measured. The company has an Anti-Corruption Policy, last amended on September 22, 2025, which is supported by periodic training sessions for employees. This policy covers all markets, but there is no evidence of customization for high-risk areas or specific effectiveness metrics. The Code of Business Conduct and Ethics addresses conflicts of interest for directors and officers, requiring authorization from the Nominating and Corporate Governance Committee or the Board of Directors, but the specific percentage of board members free from material conflicts is not disclosed.

Kind to Animals

Vera Therapeutics is not certified cruelty-free.

The company conducts pre-clinical studies on animals to assess product safety, explicitly using animal models for testing. While animal testing is a company activity, there is no information provided on a formal policy, measurable goals, or accountability regarding animal testing, nor any efforts to reduce or replace it.

Safe & Smart Tech

Vera Therapeutics maintains a Code of Business Conduct and Ethics, which is publicly available.

The company's Audit Committee is responsible for overseeing cybersecurity risk management processes, including the mitigation of risks from cybersecurity threats, and monitoring and assessing material cybersecurity breaches. The CEO and CFO concluded that, as of June 30, 2024, disclosure controls and procedures were effective. The company acknowledges its employees use generative AI technologies and the associated privacy obligations and risks. It also acknowledges being subject to stringent and evolving data privacy and security laws and regulations. In 2023, two Section 16(a) reports of change in ownership were filed late due to administrative error.

Zero Waste & Sustainable Products

Vera Therapeutics uses hazardous and flammable materials, including chemicals and biological materials, and produces hazardous waste products.

The company contracts with third parties for disposal and is committed to disposing of all waste through safe and responsible methods, aiming to minimize environmental impacts.